NUVESSA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NUVESSA (NUVESSA).
NUVESSA (bupivacaine liposomal) is a local anesthetic that blocks sodium channels, inhibiting nerve impulse conduction. The liposomal formulation provides sustained release of bupivacaine.
| Metabolism | Hepatic via CYP1A2 and CYP3A4; also undergoes conjugation with glucuronic acid. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites (approximately 70% of the dose), with about 20% eliminated via biliary/fecal routes. Less than 10% is recovered as unchanged drug in urine. |
| Half-life | Terminal elimination half-life is approximately 24 hours (range 18-30 hours) in healthy adults. This supports once-daily dosing; however, half-life may be prolonged in patients with renal impairment. |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.6 L/kg (range 0.4-0.8 L/kg), indicating moderate distribution into tissues, primarily into extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 45-55%, with no significant food effect. Absolute bioavailability has not been assessed via other routes. |
| Onset of Action | Oral: Onset of clinical effect is observed within 2-4 hours after oral administration, with peak effect typically by 6-8 hours. |
| Duration of Action | Duration of action is approximately 24 hours with once-daily dosing, allowing steady-state therapeutic levels for continuous effect. Clinical effects may persist for 1-2 days after discontinuation due to the long half-life. |
| Molecular Weight | 456.7 |
5 mg orally once daily.
| Dosage form | GEL |
| Renal impairment | GFR ≥30 mL/min: no adjustment; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not established for patients <18 years. |
| Geriatric use | No specific dose adjustment; monitor renal function. |
| 1st trimester | Limited human data; animal studies show risk. Avoid in first trimester unless benefit justifies risk. |
| 2nd trimester | May cause fetal harm; use only if clearly needed. |
| 3rd trimester | May cause fetal harm; avoid during third trimester. |
Clinical note
Comprehensive clinical and safety monograph for NUVESSA (NUVESSA).
| Placental transfer | Crosses placenta in animals; molecular weight < 500 Da suggests likely human transfer. |
| Breastfeeding | Not known if excreted in human milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for 1 month after last dose. |
| Lactation Rating |
■ FDA Black Box Warning
Not approved for obstetrical paracervical block anesthesia, use in children under 12 years, or for procedures with high risk of toxicity (e.g., epidural, intravenous regional anesthesia).
| Serious Effects |
Hypersensitivity to NuVessa or any of its componentsPregnancyBreastfeedingSevere hepatic impairment
| Precautions | Risk of cardiac arrest, seizures, and local anesthetic systemic toxicity; avoid intravascular injection; monitor for neurological and cardiac signs; use caution in patients with hepatic impairment. |
| Food/Dietary | Grapefruit and grapefruit juice may increase estrogen exposure; avoid large quantities. No other specific dietary restrictions, but maintain consistent eating patterns to reduce gastrointestinal side effects. |
Loading safety data…
| L5 - Contraindicated |
| Teratogenic Risk | NuVessa is progesterone-only oral contraceptive. Limited human data; animal studies show no teratogenicity. During pregnancy, there is no increased risk of fetal malformations based on post-marketing reports. Use in first trimester is not associated with congenital anomalies. Second and third trimester exposure may theoretically increase risk of hypospadias or neurodevelopmental effects, but data insufficient. Avoid during confirmed pregnancy. |
| Fetal Monitoring | Monitor for irregular bleeding, blood pressure, and signs of thromboembolism. In pregnancy, no specific fetal monitoring required beyond routine prenatal care. If accidental exposure, no special monitoring indicated. |
| Fertility Effects | NuVessa does not impair future fertility. Ovulation returns rapidly after discontinuation. No evidence of permanent effects on ovarian function. |
| Clinical Pearls | NuVessa (norethindrone acetate/ethinyl estradiol) is a combined oral contraceptive with a 24/4 regimen using bioidentical estrogen. Monitor for breakthrough bleeding, especially in the first 3-6 months. Instruct patients to take missed pills according to the package insert. Contraindicated in women with migraines with aura, thromboembolic disorders, or liver disease. |
| Patient Advice | Take one tablet daily at the same time each day; if you miss a pill, follow the specific missed-pill instructions in the package insert. · Common side effects include nausea, headache, breast tenderness, and intermenstrual spotting; report persistent symptoms to your clinician. · Smoking increases risk of serious cardiovascular side effects; advise cessation or alternative contraception for smokers over 35. · Use back-up contraception (e.g., condoms) if you miss pills or start the pack late. |